Is Enanta Pharmaceuticals Inc (ENTA) overvalued? · rev $65.3M
Enanta Pharmaceuticals Inc (ENTA) is a biotechnology company listed on US.
This page asks whether Enanta Pharmaceuticals Inc (ENTA) looks expensive on cached numbers — not a short thesis.
Latest reported ENTA revenue for 2025-09-30 was $65.3M. Net income was -$81.9M. Revenue was down 3.4% from 2024-09-30 to 2025-09-30. ENTA currently screens at market cap $328.0M.
ENTA currently screens at market cap $328.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ENTA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ENTA stock page for the full model, not this heading.
Not investment advice.